Jupiter Life Line Hospitals Q1 FY27 net profit falls 14.6% on Dombivli drag
Synopsis
Jupiter Life Line Hospitals grew revenue by 16.4% in Q1 FY27, but its new Dombivli facility bled ₹9.5 crore at the EBITDA level, dragging net profit down 14.6% to ₹37.5 crore. The margin squeeze tells the real story: strong top-line growth masked by the cost of expansion.
Key Takeaways
Jupiter Life Line Hospitals reported a 14.6 per cent YoY drop in net profit to ₹37.5 crore in Q1 FY27 .
Revenue from operations rose 16.4 per cent to ₹411 crore , driven by higher patient volumes.
EBITDA margin contracted to 19.3 per cent from 22.2 per cent a year earlier.
The Dombivli hospital posted an operational EBITDA loss of ₹9.5 crore in its first full quarter of operations.
Subsidiary JHPPL acquired 100 per cent of Sulcus Private Limited for ₹3.78 crore during the quarter.
Insurance empanelment at Dombivli is underway and expected to boost patient inflows in coming quarters.
Jupiter Life Line Hospitals Limited reported a 14.6 per cent year-on-year decline in consolidated net profit for the first quarter of FY27 (April–June 2025), as ramp-up losses from its newly opened Dombivli facility and elevated launch-phase marketing costs weighed on the bottom line.
Profit and Revenue Snapshot
The Mumbai-based multi-speciality hospital chain posted a net profit of ₹37.5 crore in Q1 FY27, down from ₹43.9 crore in the corresponding quarter of the previous year, according to its stock exchange filing dated 31 July. Despite the profit dip, revenue from operations climbed 16.4 per cent year-on-year to ₹411 crore from ₹353 crore, driven by stronger patient volumes across the hospital network.
EBITDA Margin Under Pressure
At the operating level, EBITDA inched up just 1.1 per cent to ₹79.3 crore from ₹78.4 crore a year earlier. However, the EBITDA margin contracted sharply to 19.3 per cent from 22.2 per cent in Q1 FY26. The company attributed the compression to initial ramp-up losses at Dombivli and higher marketing expenditure incurred during the facility's launch phase.
Dombivli Hospital: The Key Drag
The Dombivli hospital — which completed its first full quarter of operations during this period — posted an operational EBITDA loss of ₹9.5 crore, broadly matching the ₹9.4 crore loss recorded in the preceding quarter. The facility remains in the early stages of operations, though management noted that occupancy has been rising steadily, supported by growing patient footfall and an expanding range of clinical services.
Commenting on the results, Dr. Ankit Thakker, Managing Director and Chief Executive Officer, said: 'We have also initiated the process of insurance empanelment, which is expected to further improve patient inflows in the coming quarters. In line with our phased development strategy, we continue to add new specialties, strengthen our consultant base and expand service offerings to support a steady ramp-up.'
Subsidiary Acquisition
During the quarter, Jupiter Hospital Pharmacy Private Limited (JHPPL), a subsidiary of Jupiter Life Line Hospitals, acquired 100 per cent equity share capital of Sulcus Private Limited for ₹3.78 crore. Following the transaction, Sulcus has become a wholly owned subsidiary of JHPPL and a step-down subsidiary of Jupiter Life Line Hospitals.
Outlook
With insurance empanelment underway and new specialties being added at Dombivli, the company is banking on a gradual improvement in occupancy rates to restore margin levels. How quickly the Dombivli facility reaches breakeven will be the defining metric for Jupiter Life Line's profitability trajectory in the quarters ahead.
Point of View
And the Dombivli losses — nearly identical across two consecutive quarters — suggest the ramp-up is slower than the market may have priced in. The insurance empanelment signal is the right one, but empanelment timelines in Indian healthcare routinely slip. Jupiter Life Line's investment thesis now hinges on a single variable: how fast Dombivli turns EBITDA-positive. Until that clarity emerges, the margin trajectory will remain the stock's dominant overhang.
NationPress
31 Jul 2026
Frequently Asked Questions
What were Jupiter Life Line Hospitals' Q1 FY27 results?
Jupiter Life Line Hospitals reported a net profit of ₹37.5 crore in Q1 FY27 (April–June 2025), a 14.6 per cent decline from ₹43.9 crore in the same quarter last year. Revenue from operations, however, grew 16.4 per cent to ₹411 crore.
Why did Jupiter Life Line Hospitals' profit fall in Q1 FY27?
The profit decline was driven by ramp-up losses at the newly opened Dombivli hospital, which posted an operational EBITDA loss of ₹9.5 crore, and higher marketing expenditure during the facility's launch phase. These factors compressed the EBITDA margin to 19.3 per cent from 22.2 per cent a year ago.
How is the Dombivli hospital performing?
The Dombivli facility completed its first full quarter of operations in Q1 FY27 and recorded an EBITDA loss of ₹9.5 crore, similar to the ₹9.4 crore loss in the preceding quarter. Management noted that occupancy is rising steadily and that insurance empanelment has been initiated to improve patient inflows.
What acquisition did Jupiter Life Line complete in Q1 FY27?
Jupiter Hospital Pharmacy Private Limited (JHPPL), a subsidiary of Jupiter Life Line Hospitals, acquired 100 per cent of Sulcus Private Limited for ₹3.78 crore. Sulcus is now a wholly owned subsidiary of JHPPL and a step-down subsidiary of Jupiter Life Line Hospitals.
What is the outlook for Jupiter Life Line Hospitals?
The company is pursuing insurance empanelment at Dombivli and adding new specialties to drive occupancy. Management expects patient inflows to improve in coming quarters, though the pace of Dombivli's breakeven will be the key determinant of the chain's margin recovery.
